The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children

D. Ufuk Altıntas, G. Bingol Karakoc, S. Can, M. Yılmaz and S. Guneser Kendirli

Cukurova University, Department of Pediatric Allergy-Immunology, Adana, Turkey.

ABSTRACT

In this study we aimed to investigate the long term effects of inhaled steroids on linear growth, adrenal function and bone mineral density.

Thirty children with moderate asthma were randomly divided into two groups. Fifteen children (8 boys, 7 girls mean age; 10.6 ± 2.1) were treated with budesonide (group 1), and 15 (9 boys, 6 girls, mean age; 9.6 ± 2.4) with fluticasone propionate (group 2). Control group included 30 children.

Anthropometric assessment, symptom and medication scores, pulmonary functions, bone mineral density, serum and urine cortisol levels and ACTH stimulation test were evaluated at the beginning of the study and after one year period.

Symptom and medication scores, pulmonary functions improved significantly in both groups (p < 0.05). The mean annual growth was similar in group 1 and 2 and control group. Bone mineral density was comparable with control group at the beginning of the study and after one year. Mean serum cortisol level diminished at the end of the therapy but no significant differences were found between the initial and end values in respect to urine cortisol levels and cortisol/creatinin ratio. Of three groups ACTH stimulation test revealed that there were no significant difference between stdy and control groups.

In conclusion, although we did not observed any side effects of inhaled corticosteroids we suggest that children treated with inhaled corticosteroids for a long time should be followed closely with respect to side effects.

Key words: Inhaled corticosteroids. Side effects. Linear growth. Bone metabolism. Adrenal function.

RESUMEN

El presente estudio tuvo como objetivo investigar los efectos a largo plazo de los esteroides inhalados sobre el crecimiento lineal, la función adrenal y la densidad mineral ósea.

Treinta niños con asma moderada se distribuyeron aleatoriamente en dos grupos: 15 de ellos (8 niños y 7 niñas, con una media de edad de 10,6 ± 2,1 años) se trataron con budesonida (grupo 1), y los otros 15 (9 niños y 6 niñas, con una media de edad de 9,6 ± 2,4 años) con propionato de fluticasona (grupo 2). El grupo de control constaba de 30 niños.

Se realizó una exploración antropométrica, una puntuación de los síntomas y la medicación, análisis de la función pulmonar, de la densidad mineral ósea y del nivel de cortisol en sangre y orina, así como pruebas de estimulación de ACTH, tanto al principio del estudio como tras un periodo de un año.

La puntuación de los síntomas y la medicación y la función pulmonar mejoraron significativamente en ambos grupos (p < 0,05). El crecimiento medio anual...
fue similar en los grupos 1, 2 y el de control. La densidad mineral ósea fue comparable con la del grupo de control en el inicio del estudio y al cabo de un año. El nivel medio de cortisol en sangre descendió al final de tratamiento, pero no se observaron diferencias significativas entre los valores iniciales y finales con respecto al nivel de cortisol en la orina y la proporción entre cortisol y creatinina. La prueba de estimulación de ACTH no reveló diferencias significativas entre los grupos de estudio y el de control.

En conclusión, aunque no observamos ningún efecto secundario de los corticosteroides inhalados, sugerimos el control meticuloso de los posibles efectos secundarios en los niños tratados con estos fármacos de forma prolongada.


INTRODUCTION

Inhaled corticosteroids are increasingly used as maintenance treatment in childhood asthma. While inhaled corticosteroids are safer than oral corticosteroids many physicians are concerned about the potential side effects. It is still unclear whether the long term inhaled steroid usage has negative effects on growth, bone mineral density and adrenal function and there are some suspicions and worrying about its safety. There are several reports about different side effects of inhaled steroids with different dosage and duration. However most of the studies focused on particularly linear growth, adrenal suppression and bone density. Results on these side effects of inhaled steroids with different dosage and duration are conflicting. Several studies have reported poor correlation between corticosteroid-induced short term changes in the growth rate and adrenal suppression and bone density. Results on these side effects during corticosteroid therapy are conflicting.

Bone metabolism

Serum calcium, phosphorus, Alkaline Phosphatase levels, urine calcium and creatinine in 24 hours collected urine were measured and urine calcium/creatinine ratio was calculated in the beginning and at the end of the study. Bone mineral density was measured at L2-L4 vertebra by using dual energy X-Ray absorbiometry (DEXA) method before and after therapy.

Adrenal functions

Basal morning serum cortisol level, free cortisol in 24 hour urine collection, urine cortisol/creatinine ratio was evaluated in the beginning and at the end of the study. ACTH stimulation test by using synacten injection was performed before and after the study.

STATISTIC

SPSS program (version 10.0) was used for all statistical analysis. Analysis was performed by Mann Whitney-U and Wilcoxon tests. A p value less than 0.05 was considered significant.

RESULTS

Group I (budesonide group) included 15 patients. There were 8 boys (53.3%), 7 girls (46.7%) with the...
mean age of 10.6 ± 2.1 years (range: 7-13 years). Group II (fluticasone propionate group) included 9 boys (%60), 6 girls (%40) with the mean age: 9.6 ± 2.6 years (6-12 years).

Control group contained 30 patients. Of the patients 18 were boys, 12 were girls with the mean age of 9.7 ± 1.7 years.

Symptom and medication scores and pulmonary functions, were improved significantly after the inhaled steroid treatment in both groups (table I).

Anthropometric measurements and linear growth

Body mass index and weight percentiles did not change after one year in all groups (p > 0.05). The mean increase in linear growth from the beginning to the first year of the therapy was statistically significant and similar in all groups (p < 0.05). Growth rate (cm in one year) was 8.4 ± 4.6 cm in group I, 8.2 ± 6.2 and 8.1 ± 5.1 cm in group II and control group, respectively.

Growth rate was found to be smaller than 4 cm in one patient in group I (3.2 cm), in one patient in group II (2.7 cm).

Bone metabolism

There were no significant differences in serum calcium, phosphorus and ALP levels between the baseline and end values (p > 0.05) in all groups. The bone mineral density of group 1 and group 2 at the beginning and in the first year was similar (p > 0.05) and comparable with the control group (p > 0.05) (table II).

Adrenal functions

Mean basal serum cortisol level diminished at the end of the therapy but no significant differences were found between the initial and the end values in respect to the urine cortisole levels and cortisol/creatinin ratio in all groups (table III). Of three groups ACTH stimulation test revealed that there were no significant differences between group I, group II and control groups (table IV).

DISCUSSION

Inhaled corticosteroids are recommended as first line antiinflammatory therapy for the treatment of asthma. Many short and long term studies have shown ICS to be of benefit in children with asthma. However concern about the potential for systemic adverse events, including linear growth, bone metabolism, suppression of adrenal glands, has resulted in reluctance on the part of many physicians and parents to use ICS.

In this study we evaluated the long term effects of inhaled budesonide and fluticasone propionate and found that long term ICS treatment did not cause any serious side effects in children.

Linear growth

The reports on the effect of ICS have been controversial. Both retarded growth and completely normal
growth have been reported. It was concluded that there is no significant evidence of adverse effects on growth when conventional doses (< 400 μg/day) of ICS used\cite{15,18,19}.

Long term analysis of the effect of ICS on growth is available predominantly for beclametasone dipropionate. Studies have reported slowing of growth rates during the first years of budesonide treatment, these findings supports the recent studies in which impaired growth was not noticed in asthmatic children receiving ICS in doses that have been considered safe. However in our study Growth retardation was detected in two patients (one in budesonide group, one in fluticasone propionate group) for the real effect of ICS on growth of asthmatic children, good information for their growth before the treatment with ICS should be available. Most studies suffered from a lack of baseline growth velocity data, baseline differences in age and height between treatment groups, and reliance on short term measurements which do not accurately predict long term growth\cite{21}. In recent years Agertoft et al reported that growth rates were significantly reduced during the first years of budesonide treatment, these changes in growth rate were not significantly associated with adult height\cite{22}. Children with asthma who received long-term ICS attain normal adult height\cite{23,24}. A weakness of our study is that we did not have any information about baseline growth of these children. On the other hand these children should be followed for adult height. These factors should be addressed in a well designed study of drug treatments on growth.

**Bone metabolism**

Long term use of oral corticosteroids is associated with decreased bone density and an increased risk of bone fracture\cite{25}. Inhaled corticosteroids have a considerably better safety profile than oral steroids. Recent studies with ICS have yielded contradictory results, with some showing a reduction in bone mineral density whilst others have not\cite{3,4,19-29}. We have not investigated negative effect on BMD neither with budesonide nor with fluticasone propionate. Reduction in BMD has not been reported with the dosage of 200-400 μg/day whereas subtle changes have sometimes been seen with high dose therapy. However, in recent year’s negative effects of budesonide on bone turnover with the dosage of 400 μg/day has been reported\cite{30,31,32,33,36,37}.

| Table III |
| Adrenal functions of group I and group II |

<table>
<thead>
<tr>
<th></th>
<th>Before therapy</th>
<th>After therapy</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group I</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum cortisol (μg/dl)</td>
<td>15.3 ± 12.9</td>
<td>8.5 ± 7.7</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Free cortisol in 24 hour urine collection (μg/dl)</td>
<td>24.2 ± 14.1</td>
<td>24.4 ± 17.1</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Urine cortisol/creatinine</td>
<td>1.26 ± 0.85</td>
<td>1.19 ± 1.02</td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>

| **Group II** | | | |
| Serum cortisol (μg/dl) | 16.7 ± 6.9 | 10.7 ± 4.8 | < 0.05 |
| Free cortisol in 24 hour urine collection (μg/dl) | 20.3 ± 11.7 | 20.6 ± 13.6 | > 0.05 |
| Urine cortisol/creatinine | 1.26 ± 0.9 | 1.27 ± 1.02 | > 0.05 |

| Table IV |
| Comparation of groups for bone mineral density and adrenal functions after the therapy (p values) |

<table>
<thead>
<tr>
<th></th>
<th>Group I-III</th>
<th>Group II-III</th>
<th>Group I-II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear growth</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Bone mineral density</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Serum cortisol level</td>
<td>&lt; 0.05</td>
<td>&lt; 0.05</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Cortisol level in 24 hours urine sample</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Urine cortisol/creatinine</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>ACTH stimulation test</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>

We used DEXA for the evaluation of BMD. DEXA provides a measure of areal bone mineral density. And by measuring of volume of scanned bone, changes in the mineral density and bone size in growing children could be distinguished\cite{38}. Studies of biochemical markers of bone metabolism have shown a reduction in serum osteocalcin concentration, whereas other markers such as ALP and procollogen peptide I have shown less consistent results\cite{39,40}. We did not find any change in biochemical markers such as serum calcium, phosphorus, ALP levels and calcium/creatinine ratio in 24 hours collected urine. However we could not have a chance to evaluate serum osteocalcin levels because a lack of measurements techniques.

Dietary calcium intake is another important point to discuss. Some authors think that decreased BMD may be partly related with low calcium intake. Maintenance of adequate calcium and vitamin D intake thought to be helpful for negative side effects of ICS on bone turnover\cite{41,42}. We could not be able to evaluate dietary calcium intake in this study, but we did not detected reduction in calcium levels and BMD.
Adrenal Functions

HPA-axis function is an important indicator of systemic exposure to corticosteroid therapy. Studies of the incidence of adrenal suppression in asthmatic children receiving ICS have revealed conflicting results. Mild to moderate HPA suppression, symptomatic adrenal insufficiency and normal adrenal function were reported in different studies. The results are conflicting mainly because the investigations have often been uncontrolled, patients have previously received oral steroids, the duration of therapy have varied, different inhalers have been used, and different tests have been applied to monitor changes in HPA-axis function.

Various tests have been used to evaluate HPA-axis function including measurement of basal morning plasma cortisol concentration, integrated plasma cortisol concentration over the course of >12 to 24 hours, urinary free cortisol concentration and ACTH stimulation test. In this study we evaluated HPA-axis function by using measurement of basal morning plasma cortisol concentration, urinary free cortisol concentration and ACTH stimulation test. We found that basal morning plasma cortisol concentration was decreased after ICS treatment. Similar to our results lower levels of morning cortisol were found in asthmatic receiving budesonide, beclamethasone propionate, and fluticasone propionate. The ACTH stimulation test and 24 hour integrated plasma cortisol concentration are methods recommended by the US Food and Drug Administration (FDA) to evaluate HPA-axis evaluation. No significantly changes were detected ACTH stimulation test in our study. Adrenal suppression could occur in children with the use of 400-1000 mg/day budesonide. In another report it was detected that fluticasone propionate exhibited at least two fold greater adrenal suppression than budesonide on a microgram equivalent basis. Free cortisol in the urine (UFC) is frequently measured in clinical research to assess whether inhaled corticosteroids (ICS) cause suppression of the hypothalamic-pituitary-adrenal axis. We also evaluated urinary free cortisol concentration. However it was thought to be an unreliable surrogate marker of adrenal suppression.

We did not observe any serious effects on adrenal glands; we think that it may because we used conventional doses in our patients. In conclusion we observed that long-term usage of inhaled steroids (250-400 g/day) did not have any important side effects on linear growth, bone metabolism and adrenal functions, however we suggest that children treated with inhaled corticosteroids for a long time should be followed closely with respect to side effects.

REFERENCES

20. Reilly SM, Hambleton G, Adams JE, Mughal MZ. Bone densi-
budesonide on serum markers of bone metabolism in chil-
22. Wśńiewski AP, Lewis AS, Gren DJ. Cross sectional investiga-
tion of the effects of inhaled corticosteroids on bone density
and bone metabolism in patients with asthma. Thorax 1997;
52:853-60.
23. Toogod JH, Baskerville J, Mankov AE, et al. Bone mineral den-
sity and the risk of fracture in patients receiving long-term in-
inhaled corticosteroids on bone metabolism in prepubertal
teroids and bone density of children with asthma. J Asthma.
26. Medici TC, Grebski E, Hacki M, et al. Effect of one year treat-
ment with inhaled fluticasone propionate or beclomethasone
dipropionate on bone density and bone metabolism: a ran-
donised parallel group study in adult asthmatic subjects. Tho-
onide by means of turbuhaler on hypothalamic-pituitary-adren-
28. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal su-
pression with inhaled budesonide and fluticasone propionate
1997;76:405-10.
30. Patel L, Patel HK, Kibru MG. Symptomatic adrenal insuffi-
ciency during inhaled corticosteroid treatment. Arch Dis Child.
pression in asthmatic children receiving low-dose inhaled
budesonide: comparison between dry powder inhaler and pres-
32. Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to
adrenal suppression secondary to high-dose nebulized corti-
33. Todd GR, Acarini CL, Buck JJ, et al. Acute adrenal crisis in
asthmatics treated with high-dose fluticasone propionate. Eur
34. Irani AM, Rivera MC, Fitzpatrick S. Effects of budesonide in-
halation on HPA-axis function in infants and young children
with persistent asthma. Ann Allergy Asthma Immunol. 2002;
88:306-12.
rush immunotherapy with a standardized allergen an alun ad-
juved pyridine extracted material in grass pollen allergy. Clin
36. Agarwood L, Pedersen S. Effects of long term treatment with
an inhaled corticosteroid on growth and pulmonary function in
markers of bone metabolism in relation to adrenocortical and
growth suppression during the initiation phase of inhaled
of High-dose inhaled steroids on bone density and calcium
39. Teelucksingh S, Padfield PL, Tis L, et al. Inhaled steroids,
steroids reduce bone formation showing by plasma osteocal-
41. Johnston CC, Miller JZ, Slemenda CW. Calcium supplemen-
tation and increases in bone mineral density in children. N